GW Pharmaceuticals (GWP)

Business description

GW Pharmaceuticals is a UK-based speciality pharma company focused on developing cannabinoid medicines. Lead product, Sativex, is marketed in a number of European countries for multiple sclerosis-associated spasticity.

Share price chart

Share chart

Stock data

Market cap.£1028.4m
Last close438.000p
High / Low (52 weeks)523.5p / 48.0p
Stock market listingAIM, NASDAQ
Forecast net cash (£m)79
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual0.943.4803.1
Relative *1.542.0775.6

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Pharmaceuticals Acorda Therapeutics
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
AmpliPhi Biosciences Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Arena Pharmaceuticals Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Avita Medical Basilea
Bavarian Nordic Bellus Health
Benitec Biopharma BioAlliance Pharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron BTG
Can-Fite BioPharma Capstone Therapeutics
Cardio3 BioSciences Celldex Therapeutics
Cellectis Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Clinuvel
Consort Medical Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Genfit Genmab
GeoVax GI Dynamics
Gilead Sciences Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
LCA-Vision LeMaitre Vascular
Lifeline Scientific Ligand Pharmaceuticals
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onyx Pharmaceuticals
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Regeneus ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trillium Therapeutics Trimel Pharmaceuticals
UCB uniQure NV
United Drug Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Xencor Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Citigroup Inc. Lowers GW Pharmaceuticals PLC- Price Target to $86.00 (GWPH)

Wed, 02 Jul 2014 12:27:59 GMT

Piper Jaffray Reiterates Overweight Rating for GW Pharmaceuticals PLC- (GWPH)

Mon, 30 Jun 2014 12:33:45 GMT

GW Pharmaceuticals Closes US Public Offering; Cannabis-Based Medicines ...

Fri, 27 Jun 2014 02:49:39 GMT

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of ...

Wed, 25 Jun 2014 15:11:15 GMT

Stock Watch: GW Pharmaceuticals PLC- ADR (GWPH)

Sun, 13 Jul 2014 23:43:20 GMT

Y/E Sep Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2012A 33.1 2.8 2.2 2.6 168.5 424.3
2013A 27.3 (8.9) (9.7) (2.6) N/A N/A
2014E 24.5 (19.4) (19.6) (7.6) N/A N/A
2015E 28.6 (11.6) (12.0) (3.7) N/A N/A

Last updated on 26/06/2014

Investment summary

Twelve-week data in 27 children/young adults from open label physician-led Epidolex studies in treatment-resistant epilepsy show encouraging results. After 12 wks of therapy, 48% of pts had a >50% reduction in seizure frequency vs baseline, four pts were seizure free, with a mean overall reduction in seizure frequency of 44%. The nine Dravet Syndrome pts had a mean 52% overall reduction in convulsive seizures with a third having a 75-100% frequency decrease. Safety data in 62 pts indicates that 80% of adverse events were mild-to-moderate. These data support the design of the Epidiolex Phase II/III study in Dravet Syndrome due to start in H214. The FDA has granted fast-track status. GW, under its shelf registration, intends to sell 1.7m ADSs (1.2m new ADSs and 500k of ADSs being sold by the directors) at an as yet undetermined price in an underwritten offering.

Last updated on 30/06/2014

Industry outlook

GW is the leader in the field of cannabinoid medicines, which have the potential to become novel therapies for a broad range of diseases. Cannabinoids are diverse chemical compounds that GW extracts from different cannabis plant varieties (chemotypes) it has bred. Sativex is GW’s lead product; we estimate it will achieve 5-10% market share in its approved indications.

Last updated on 30/06/2014

Key management

Geoffrey Guy, Chairman
Justin Gover, CEO
Adam David George, CFO

Company address

6th Floor
1 Cavendish Place
London
W1G 0QF
United Kingdom
+44 (0) 1980 557 000
View website